Tobacco abstinencewas established and confirmed by
exhaled carbon monoxide measurements at TQD and at intervals thereafter up to 24 weeks.
The primary end point was the 4-week exhaled carbon monoxide–confirmed continuous
abstinence rate for weeks 9 through 12 of treatment, ie, the proportion of participants able to
maintain complete abstinence from smoking for the last 4 weeks of treatment, as assessed
using multiple imputation analysis. Secondary end points included point prevalence
abstinence at 6 months, continuous abstinence rate from weeks 9 through 24, and adverse
events. Multiple imputation also was used to address loss to follow-up.